Patient-derived mini-colons enable long-term modeling of tumor–microenvironment complexity.
- Published in:
- Nature Biotechnology, 2025, v. 43, n. 5, p. 727, doi. 10.1038/s41587-024-02301-4
- By:
- Publication type:
- Article
Works by Langer, Jakob
Results: 29
1
2
The Cost of Seasonal Influenza: A Systematic Literature Review on the Humanistic and Economic Burden of Influenza in Older (≥ 65 Years Old) Adults.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 3, p. 945, doi. 10.1007/s12325-023-02770-0
- By:
- Publication type:
- Article
3
Understanding the Global Burden of Influenza in Adults Aged 18–64 years: A Systematic Literature Review from 2012 to 2022.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 10, p. 4166, doi. 10.1007/s12325-023-02610-1
- By:
- Publication type:
- Article
4
High Clinical Burden of Influenza Disease in Adults Aged ≥ 65 Years: Can We Do Better? A Systematic Literature Review.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 4, p. 1601, doi. 10.1007/s12325-023-02432-1
- By:
- Publication type:
- Article
5
A Japanese Study Assessing Glycemic Control with Use of IDegAsp Co-formulation in Patients with Type 2 Diabetes in Clinical Practice: The JAGUAR Study.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 3, p. 1638, doi. 10.1007/s12325-021-01623-y
- By:
- Publication type:
- Article
6
Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
- Published in:
- Advances in Therapy, 2021, v. 38, n. 1, p. 721, doi. 10.1007/s12325-020-01561-1
- By:
- Publication type:
- Article
7
Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis.
- Published in:
- Advances in Therapy, 2020, v. 37, n. 10, p. 4446, doi. 10.1007/s12325-020-01476-x
- By:
- Publication type:
- Article
8
Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.
- Published in:
- 2017
- By:
- Publication type:
- journal article
9
Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA.
- Published in:
- 2017
- By:
- Publication type:
- journal article
10
Impact of Medication Adherence and Persistence on Clinical and Economic Outcomes in Patients with Type 2 Diabetes Treated with Liraglutide: A Retrospective Cohort Study.
- Published in:
- Advances in Therapy, 2015, v. 32, n. 4, p. 341, doi. 10.1007/s12325-015-0199-z
- By:
- Publication type:
- Article
11
Clinical effectiveness of liraglutide across body mass index in patients with type 2 diabetes in the United States: a retrospective cohort study.
- Published in:
- 2014
- By:
- Publication type:
- journal article
12
Clinical Effectiveness of Liraglutide Across Body Mass Index in Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study.
- Published in:
- Advances in Therapy, 2014, v. 31, n. 9, p. 986, doi. 10.1007/s12325-014-0153-5
- By:
- Publication type:
- Article
13
Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide.
- Published in:
- Advances in Therapy, 2014, v. 31, n. 2, p. 202, doi. 10.1007/s12325-014-0098-8
- By:
- Publication type:
- Article
14
Protein Spin Labeling with a Photocaged Nitroxide Using Diels–Alder Chemistry.
- Published in:
- ChemBioChem, 2019, v. 20, n. 19, p. 2479, doi. 10.1002/cbic.201900318
- By:
- Publication type:
- Article
15
Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
- Published in:
- Journal of Medical Economics, 2018, v. 21, n. 11, p. 1110, doi. 10.1080/13696998.2018.1513406
- By:
- Publication type:
- Article
16
Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
- Published in:
- 2018
- By:
- Publication type:
- journal article
17
Understanding the Barriers and Attitudes toward Influenza Vaccine Uptake in the Adult General Population: A Rapid Review.
- Published in:
- Vaccines, 2023, v. 11, n. 1, p. 180, doi. 10.3390/vaccines11010180
- By:
- Publication type:
- Article
18
Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 2, p. 613, doi. 10.1007/s13300-020-00985-w
- By:
- Publication type:
- Article
19
Quality of Life and Utility Values for Cost-Effectiveness Modeling in Japanese Patients with Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 12, p. 2931, doi. 10.1007/s13300-020-00938-3
- By:
- Publication type:
- Article
20
Response to "Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment".
- Published in:
- 2020
- By:
- Publication type:
- Letter
21
Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 4, p. 1347, doi. 10.1007/s13300-019-0635-1
- By:
- Publication type:
- Article
22
Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment.
- Published in:
- Diabetes Therapy, 2019, v. 10, n. 2, p. 735, doi. 10.1007/s13300-019-0591-9
- By:
- Publication type:
- Article
23
A Network Meta-Analysis Comparing Semaglutide Once-Weekly with Other GLP-1 Receptor Agonists in Japanese Patients with Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2018, v. 9, n. 3, p. 973, doi. 10.1007/s13300-018-0397-1
- By:
- Publication type:
- Article
24
IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting.
- Published in:
- Diabetes Therapy, 2017, v. 8, n. 3, p. 531, doi. 10.1007/s13300-017-0251-x
- By:
- Publication type:
- Article
25
Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis.
- Published in:
- Diabetes Therapy, 2017, v. 8, n. 1, p. 85, doi. 10.1007/s13300-016-0217-4
- By:
- Publication type:
- Article
26
Real-World Clinical and Economic Outcomes of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus in the United States.
- Published in:
- Diabetes Therapy, 2014, v. 5, n. 2, p. 579, doi. 10.1007/s13300-014-0084-9
- By:
- Publication type:
- Article
27
Electron interactions with Bis(pentamethylcyclopentadienyl) titanium(IV) dichloride and difluoride.
- Published in:
- European Physical Journal D (EPJ D), 2018, v. 72, n. 6, p. 1, doi. 10.1140/epjd/e2018-80794-6
- By:
- Publication type:
- Article
28
Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs: Results from a Japanese cohort study (JDDM53).
- Published in:
- Journal of Diabetes Investigation, 2021, v. 12, n. 3, p. 374, doi. 10.1111/jdi.13352
- By:
- Publication type:
- Article
29
The association of body mass index with the risk of type 2 diabetes: a case—control study nested in an electronic health records system in the United States.
- Published in:
- Diabetology & Metabolic Syndrome, 2014, v. 6, n. 1, p. 1, doi. 10.1186/1758-5996-6-50
- By:
- Publication type:
- Article